NFKB1 and prostate carcinoma: As becomes evident in Figure 5, testosterone-BSA treatment inhibits NF-κB activity in DU145 cells in agreement with the capacity of testosterone-BSA to induce apoptosis by down-regulating several pro-survival pathways in prostate cancer cells.